A randomized, controlled trial (RCT) shows that even at a higher dose and longer treatment duration, the antimalarial drug ivermectin didn't shorten the time to a sustained recovery from COVID-19.
A randomized, controlled trial (RCT) shows that even at a higher dose and longer treatment duration, the antimalarial drug ivermectin didn't shorten the time to a sustained recovery from COVID-19.
"Our findings are concerning, as even people with a mild case of COVID-19 are showing changes in their brains months later. More studies are needed to hopefully identify treatments to prevent any long-term effects on people's quality of life," she added.
What happened to the variants that once wreaked havoc? “For all intents and purposes, we can consider them gone,” said David Dowdy, an epidemiology professor at Johns Hopkins Bloomberg School of Public Health.
Recent Comments